Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the months of May and June. On May 15, 2024, at 3:15 p.m. EST, Trey Martin, Chief Executive Officer and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the RBC Healthcare Conference in New York City, NY. On June 11, 2024, at 1:20 p....
ACV to Participate in Upcoming Investor Conferences BUFFALO, N.Y., May 09, 2024 (GLOBE NEWSWIRE) -- ACV (Nasdaq: ACVA), a leading digital automotive marketplace and data services partner for dealers and commercial clients, announced today that members of its management team will present at the following upcoming investor conferences: 19th Annual Needham Technology, Media, & Consumer Conference on Thursday, May 16, 2024 at 11:00 a.m. ET52nd Annual J.P. Morgan Global Technology, Media and Communications Conference on Tuesday, May 21, 2024 at 4:25 p.m. ET Webcasts of these events will be a...
Royalty Pharma Reports First Quarter 2024 Results Royalty Receipts growth of 14% driving Portfolio Receipts of $717 millionNet cash provided by operating activities of $665 millionFull year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 millionCommitment to grow dividend by mid-single digit percentage annually NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 2024 guidance for Portfolio Receipts. “We continued to execute on our strategy in the f...
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma’s development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in annual peak royalties Royalty Pharma to highlight the strength of its development-stage pipeline on its first quarter of 2024 financial results call today at 8:00 a.m. NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (N...
Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was to Participate in the 19th Annual Needham Technology, Media, & Consumer Conference ATLANTA, May 08, 2024 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE: OXM) today announced the Company will be participating in the 19th Annual Needham Technology, Media, & Consumer Conference being held at The Westin Grand Central Hotel in New York, New York on Tuesday, May 14, 2024. About OxfordOxford Industries, Inc., a leader in the apparel industry, owns and markets the distinctive Tommy Bahama®, Lilly Pulitzer®, Johnny Was®, Southern Tid...
Maravai LifeSciences Reports First Quarter 2024 Financial Results Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $64.2 million, Net loss of $(22.7) million, and Adjusted E...
ACV’s Data-Driven Solutions Drive Profits and Optimize Inventory for Dealerships Lester Glenn Auto Group unlocks increased revenue and operational efficiencies with ClearCar, ACV MAX and ACV Auctions BUFFALO, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ACVA), the leading digital automotive marketplace and data services partner for dealers and commercial clients, is delivering innovative solutions to more dealers across the country who are navigating the complexities of the current automotive market, including lean inventory and pricing fluctuations. ACV’s winning combination of pro...
ACV Announces First Quarter 2024 Results Delivered 22% Revenue GrowthRevenue and Adjusted EBITDA at the High-End of Guidance First quarter revenue of $146 millionFirst quarter GAAP net income (loss) of ($20) millionFirst quarter non-GAAP net income of $1 millionFirst quarter Adjusted EBITDA of $4 millionExpects 2024 revenue of $610 million to $625 million, growth of 27% to 30% YoY, net income (loss) of ($85) million to ($80) million and Adjusted EBITDA of $20 million to $25 million BUFFALO, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- ACV (Nasdaq: ACVA), a leading digital automotive m...
HighPeak Energy, Inc. Announces First Quarter 2024 Financial and Operating Results FORT WORTH, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter ended March 31, 2024. HighlightsFirst Quarter 2024 Sales volumes averaged 49,729 barrels of crude oil equivalent per day (“Boe/d”), consisting of 80% crude oil and 91% liquids, representing a 34% increase over first quarter 2023.Lease operating expenses, excluding expense workovers, were reduced for the fourth consecutive qua...
SINGAPORE--(BUSINESS WIRE)-- Northern Trust (Nasdaq: NTRS) today announced that it has been selected to provide outsourced trading via its Integrated Trading Solutions (ITS) for New Silk Road Investment Pte Ltd., a Singapore-based investment manager. Founded in 2009, New Silk Road invests in Asian companies with the goal to achieve long-term returns. In addition to the new remit for trading services, Northern Trust continues to provide global custody services for New Silk Road funds which it has done since 2011. “New Silk Road came to us looking for a solution to help navigate cross-border...
Lyell Immunopharma to Participate in BofA Securities Health Care Conference SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the BofA Securities 2024 Health Care Conference on Tuesday, May 14 at 8:40 am PT. A live webcast of the presentation can be accessed through the Investors section of the Company's website at Following the live ...
Dorman Products, Inc. Reports First Quarter 2024 Results Highlights (All comparisons are to the prior year period unless otherwise noted): Net sales of $468.7 million, up 0.4% compared to $466.7 millionDiluted earnings per share (“EPS”) of $1.05, up 483% compared to $0.18Adjusted diluted EPS* of $1.31, up 134% compared to $0.56Generated $52 million of cash from operating activities; repaid $15 million of debt and repurchased $27 million of its sharesThe Company confirms its full-year 2024 guidance COLMAR, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Dorman Products, Inc. (the “Company” or ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.